Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 11/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12226594 | 0.82 | HTT (0.46) | ADRB3HTTDPP4EPHX2EPHX1 | |
| SCHEMBL10231087 | 0.82 | HTT (0.46) | ADRB3HTTDPP4EPHX2EPHX1 | |
| SCHEMBL21518364 | 0.81 | ADRB3 (0.41) | ADRB3HTTDPP4EPHX2EPHX1 | |
| SCHEMBL5504092 | 0.80 | GRIN2D (0.49) | DPP4EPHX2 | |
| SCHEMBL353997 | 0.78 | ADRB3 (0.39) | ADRB3HTTDPP4EPHX2KMT2A | |
| SCHEMBL5505001 | 0.74 | HTT (0.36) | ADRB3HTTDPP4EPHX2DPP7 | |
| SCHEMBL21398769 | 0.72 | EPHX2 (0.39) | EPHX2KMT2A | |
| SCHEMBL5507394 | 0.71 | CA1 (0.37) | DPP4EPHX2SMN1; SMN2 | |
| SCHEMBL18747628 | 0.70 | DPP4 (0.45) | DPP4EPHX2EPHX1 | |
| SCHEMBL13360905 | 0.68 | TSHR (0.43) | ADRB3HTTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828111-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006059252-A2 | METHODS AND FLUORINATED COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | ADRB3 535/4885HTT 16/4885DPP4 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.